Ruxolitinib is the first JAK inhibitor approved as therapy for highand intermediate-risk myelofibrosis (MF). Two phase 3 trials have shown that ruxolitinib provides significant clinical benefit to patients with MF by reducing spleen size and ameliorating debilitating disease-related constitutional symptoms. 1, 2 Patients participating in both studies were required to have clinically significant splenomegaly (at least 5 cm by palpation). Therapeutic benefit of ruxolitinib in patients without splenomegaly has never been documented. We recently reported long-term experience with ruxolitinib in 107 patients with advanced MF who participated in the phase 1-2 study at our center. 3 Six patients from this study ( Table 1) did not have palpable splenomegaly (4 had prior splenectomy). We describe their outcome in this letter.
Ruxolitinib improved disease-related symptoms in all patients within the first month of therapy. There was significant improvement in fatigue in all patients and resolution of drenching night sweats (2 patients), itching (2 patients), and bone pain and skin rash thought to be paraneoplastic (1 patient). Five patients had weight gain (up to 17%). Three of the splenectomized patients had abdominal pain and discomfort due to hepatomegaly. After 2 weeks of therapy, reduction of liver size could be appreciated that eventually decreased by 50%-68% (16 to 5 cm, 16 to 5 cm, and 14 to 7 cm, respectively). Time to best response varied from 3-24 months, a slower pace of reduction than reported for the response in splenomegaly. 1, 2 Patients with marked leukocytosis and thrombocytosis normalized their blood counts. Treatment was well tolerated without drug interruptions due to toxicity. Adverse effects were limited to grade 3 myelosuppression (thrombocytopenia ϫ1, anemia ϫ2), requiring dose modification in 3 patients. No significant (grade 3 or 4) nonhematologic adverse events were observed. Median duration of therapy is 36 months (range 21-54ϩ). Four patients discontinued ruxolitinib due to transformation to acute myeloid leukemia (AML; patient 1), disease progression (patient 4), or death due to other medical reasons (patients 2 and 3). Patient 1 had abnormal cytogenetics and 11% blasts in the bone marrow while starting therapy with ruxolitinib; he did not progress to AML for 2 years. Instead, he gained weight and improved his performance status, and is now in remission 30 months after induction chemotherapy and unrelated-donor hematopoietic stem cell transplantation. Two patients are continuing ruxolitinib after more than 54 and 45 months (patients 5 and 6, respectively). Particularly in patient 6 (who had very high WBC count and complex cytogenetics; very high-risk MF with expected average survival of only 9 months), an excellent disease control was observed. 1, 3 In this small cohort of patients, we could witness a positive effect of ruxolitinib on patient symptoms not related to reduction of spleen size. As the liver becomes the primary site of extramedullary hematopoiesis in patients after splenectomy it seems to respond to ruxolitinib in a similar way. Overall, treatment with ruxolitinib alleviates symptom burden and improves quality of life of patients with advanced MF without clinically significant splenomegaly. To the editor:
Ohad Benjamini

Intravenous immunoglobulin (IVIg) inhibits CD8 cytotoxic T-cell activation
We recently reported that intravenous immunoglobulin (IVIg) interferes with the binding of ovalbumin immune complexes (OVA-IC) to phagocytic Fc␥Rs, leading to a decreased internalization inside antigen-presenting cells (APCs) and resulting in a reduced amount of antigen presented by MHC II molecules to CD4 helper T cells. 1 Consequently, the antigen-specific helper T-cell response is dampened in the presence of IVIg. In the context of autoimmune diseases, these observations suggest that IVIg treatment could decrease the presentation of self-antigens to CD4 T cells and prevent the subsequent autoantibody production.
Although CD8 cytotoxic T cells play a substantial role in organ destruction in several autoimmune diseases, 2-4 the effect of IVIg on this cell compartment has not been studied so far. We hypothesized that CD8 T-cell activation could be impaired in the presence of IVIg, by a mechanism similar to that described for CD4 T-cell activation. We thus used OT-II (CD4) I-Ab-restricted OVAspecific primary T cells 5 to first confirm that the previously reported inhibitory effect of IVIg was not limited to I-Ad-restricted OVA-specific CD4 T cells (DO-11.10). 1 We also used OT-I (CD8) H2K b -restricted OVA-specific T cells 6 to determine the effect of IVIg on the ability of APCs to activate CD8 T cells by crosspresentation of OVA-IC. OT-I and OT-II cells were purified from the spleen and lymph nodes of C57BL/6-Tg(TcraTcrb)1100Mjb/J and B6.Cg-Tg(TcraTcrb)425Cbn/J mice, respectively. Bone marrow-derived dendritic cells (BMDCs) from C57BL/6 mice were prepared as previously described 1 and used as APCs to activate OT-I and OT-II cells in the presence of OVA-IC, with or without IVIg. T-cell activation was determined by flow cytometry using CD69 expression as a marker of cell activation. 7 Our results first show an increased proportion of OT-II cells expressing CD69 after OVA-IC presentation, from a background level of 3% up to 74% (Figure 1 top left and middle panels) . When IVIg was present during OVA-IC presentation, the percentage of cells expressing CD69 only reached 10% (Figure 1 top right panel) , indicating that OT-II cell activation was significantly impaired in the presence of IVIg. The inhibitory effect of IVIg on OT-II cell activation is thus similar to that previously observed with DO-11.10 cells, regardless of their different MHC restriction profile. Our results also reveal the efficient activation of OT-I cells by OVA-IC cross-presentation, as shown by the increase from a background level of 1% to a proportion of 29% of C69-expressing cells ( Figure 1 bottom left and middle panels) . However, the presence of IVIg completely prevented OT-I cell activation, as illustrated by the absence of induction of CD69 on these cells (bottom right panel).
The effect of IVIg on CD8 T-cell activation by crosspresentation of immune complexes was predictable, because CD8 T-cell activation requires signals provided by antigenic epitopes presented on MHC I molecules. 8, 9 We herein provide the experimental demonstration of this inhibitory effect. Whether the interference of IVIg with immune complex uptake by APCs is solely responsible for this inhibition remains to be determined. Kaveri et al previously showed that IVIg contains antibodies specific to a highly conserved portion of human HLA class I antigens and that these antibodies were able to inhibit class I-restricted T cellmediated cytotoxicity. 10 However, we did not observe MHC I blockade by IVIg in our assays, suggesting that HLA class Equal numbers of bone marrow-derived dendritic cells (BMDCs) and OT-II (top panels) or OT-I (bottom panels) cells were incubated for 3 days in the presence of 2.5 g/mL of OVA-IC prepared as described previously, 1 with or without 10 mg/mL of IVIg (Gamunex). The background activation was established in the absence of OVA-IC (left panels). After incubation, the cells were recovered, washed and labeled with either anti-CD4-FITC or anti-CD8-PE and anti-CD69-APC (eBioscience). T-cell activation was determined by measuring the expression of CD69 on CD4-(top panels) or CD8-(bottom panels) gated cells by flow cytometry (Accuri C6 flow cytometer). The data were analyzed using the FCS Express 4.0 software (De Novo) and are representative of 4 independent experiments done with different lots of BMDCs.
